Connecting Hope and
Medical Science


CCRP Clinical Trials

Click here for Physician Area

Only show trials for the disease site :

Biomarker AnalysisEAY131UOPENMATCH Treatment Subprotocol U: VS-6063 (defactinib) in Patients with Tumors with NF2 Loss
Biomarker AnalysisEAY131SUSPENDEDMolecular Analysis for Therapy Choice (MATCH)
Biomarker AnalysisEAY131HOPENMATCH Treatment Subprotocol H: Phase II Study of Dabrafenib and Trametinib in Patients with tumors with BRAF V600E or V600K mutations (excluding melanoma and thyroid cancer)
Biomarker AnalysisEAY131FOPENMATCH Treatment Subprotocol F: Crizotinib in Patients with Tumors (other than adenocarcinoma of lung or ALCL) with ALK Translocations
Biomarker AnalysisEAY131ROPENMATCH Treatment Subprotocol R: Phase II Study of Trametinib in patients with BRAF fusions, or with non-V600E, nonV600K BRAF mutations
Biomarker AnalysisEAY131VOPENMATCH Treatment Subprotocol V: Phase II Study of Sunitinib in Patients with Tumors with cKIT Mutations (Excluding GIST, Renal Cell Carcinoma or Pancreatic Neuroendocrine Tumor)
Biomarker AnalysisEAY131GOPENMATCH Treatment Subprotocol G: Phase II study of Crizotinib in patients with ROS1 Translocations (other than patients with nonsmall cell lung cancer)
Biomarker AnalysisEAY131AOPENMATCH Treatment Subprotocol A: Phase II Trial of Afatinib in Patients with Solid Tumors (Other Than Small Cell and Non-Small Cell Lung Cancer) or Lymphomas, That Have Activating Mutations of EGFR and Have Progressed After Standard Treatment
Biomarker AnalysisEAY131BOPENMATCH Treatment Subprotocol B: Phase II Study of Afatinib in Patients with Tumors with HER2 Activating Mutations
Biomarker AnalysisEAY131QOPENMATCH Treatment Subprotocol Q: EAY131-Q: Ado-trastuzumab Emtansine in Patients with Tumors with HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas)